A Phase 1/2, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacodynamics, and Pharmacokinetics of Zilebesiran in Japanese Patients With Mild to Moderate Hypertension
Latest Information Update: 03 Sep 2024
At a glance
- Drugs Zilebesiran (Primary)
- Indications Hypertension
- Focus Adverse reactions
- Sponsors Alnylam Pharmaceuticals
Most Recent Events
- 29 Aug 2024 Status changed from recruiting to active, no longer recruiting.
- 28 Jun 2024 Status changed from not yet recruiting to recruiting.
- 23 May 2024 New trial record